Pneumococcal vaccination in elderly care facilities in Japan: A cross-sectional, web-based survey.

IF 3.5 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-07 DOI:10.1080/21645515.2025.2461814
Youngju Kim, Hironori Taniguchi, Kotoba Okuyama, Junpei Kamimoto, Kenji Kawakami
{"title":"Pneumococcal vaccination in elderly care facilities in Japan: A cross-sectional, web-based survey.","authors":"Youngju Kim, Hironori Taniguchi, Kotoba Okuyama, Junpei Kamimoto, Kenji Kawakami","doi":"10.1080/21645515.2025.2461814","DOIUrl":null,"url":null,"abstract":"<p><p>This study evaluated pneumococcal vaccination status using evaluable data collected from 445 of 1,313 managing directors of elderly care facilities in Japan through an online survey (September 5, 2022-November 25, 2022; UMIN000048747); comparisons were made with the influenza (2021-2022 vaccination only) and coronavirus disease 2019 (COVID-19) vaccination status. Among facilities who kept pneumococcal vaccination records (<i>n</i> = 42), the mean pneumococcal vaccination rate was 31.1%, with the rate being higher for the influenza (93.1%; <i>n</i> = 234) and COVID-19 (94.3%; <i>n</i> = 285) vaccines. Overall, excluding facilities that answered that the corresponding vaccine status at their sites was unknown, the percentage of facilities with high vaccination rates (80% to 100%) was substantially higher for the influenza (80.5%; 351/436) and COVID-19 (89.6%; 396/442) vaccines than for the pneumococcal vaccine (6.5%; 24/370). Multivariable analysis showed that major factors associated with a high pneumococcal vaccination rate (≥15%) were \"managing director's willingness to recommend\" and \"pneumococcal vaccination request from the residents.\" The most common reason for their willingness to recommend the pneumococcal vaccine was that it is an effective disease prevention strategy (83.3%; 65/78) and for their unwillingness to recommend the pneumococcal vaccine was the inability to understand the effectiveness of the vaccine (43.6%; 17/39). In conclusion, there is a need to improve pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as increasing awareness and encouraging pneumococcal vaccine recommendation among managing directors, especially for residents not eligible for the national subsidy program, and providing regular training on the pneumococcal vaccine for staff and residents are required.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2461814"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11810092/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2461814","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study evaluated pneumococcal vaccination status using evaluable data collected from 445 of 1,313 managing directors of elderly care facilities in Japan through an online survey (September 5, 2022-November 25, 2022; UMIN000048747); comparisons were made with the influenza (2021-2022 vaccination only) and coronavirus disease 2019 (COVID-19) vaccination status. Among facilities who kept pneumococcal vaccination records (n = 42), the mean pneumococcal vaccination rate was 31.1%, with the rate being higher for the influenza (93.1%; n = 234) and COVID-19 (94.3%; n = 285) vaccines. Overall, excluding facilities that answered that the corresponding vaccine status at their sites was unknown, the percentage of facilities with high vaccination rates (80% to 100%) was substantially higher for the influenza (80.5%; 351/436) and COVID-19 (89.6%; 396/442) vaccines than for the pneumococcal vaccine (6.5%; 24/370). Multivariable analysis showed that major factors associated with a high pneumococcal vaccination rate (≥15%) were "managing director's willingness to recommend" and "pneumococcal vaccination request from the residents." The most common reason for their willingness to recommend the pneumococcal vaccine was that it is an effective disease prevention strategy (83.3%; 65/78) and for their unwillingness to recommend the pneumococcal vaccine was the inability to understand the effectiveness of the vaccine (43.6%; 17/39). In conclusion, there is a need to improve pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as increasing awareness and encouraging pneumococcal vaccine recommendation among managing directors, especially for residents not eligible for the national subsidy program, and providing regular training on the pneumococcal vaccine for staff and residents are required.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本老年护理机构的肺炎球菌疫苗接种:一项基于网络的横断面调查。
本研究通过在线调查(2022年9月5日- 2022年11月25日;UMIN000048747);与流感(仅2021-2022年疫苗接种)和2019冠状病毒病(COVID-19)疫苗接种状况进行比较。在保存肺炎球菌疫苗接种记录的机构(n = 42)中,平均肺炎球菌疫苗接种率为31.1%,流感疫苗接种率较高(93.1%;n = 234)和COVID-19 (94.3%;N = 285)疫苗。总的来说,除去那些回答其地点的相应疫苗状况未知的设施外,流感疫苗接种率高(80%至100%)的设施的百分比要高得多(80.5%;351/436)和COVID-19 (89.6%;396/442)疫苗比肺炎球菌疫苗(6.5%;24/370)。多变量分析显示,与高肺炎球菌接种率(≥15%)相关的主要因素是“总经理推荐意愿”和“居民肺炎球菌疫苗接种要求”。他们愿意推荐肺炎球菌疫苗的最常见原因是这是一种有效的疾病预防策略(83.3%;65/78),不愿意推荐肺炎球菌疫苗的原因是无法了解疫苗的有效性(43.6%;17/39)。总之,有必要提高日本老年护理机构的肺炎球菌疫苗接种率。需要采取一些战略,例如提高管理主任的认识并鼓励他们推荐肺炎球菌疫苗,特别是对没有资格享受国家补贴方案的居民,并定期为工作人员和居民提供肺炎球菌疫苗培训。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
CiteScore
7.90
自引率
8.30%
发文量
489
审稿时长
3-6 weeks
期刊介绍: (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
期刊最新文献
Changes in 23-valent pneumococcal polysaccharide vaccination rate and associated factors in 2022 and 2024 among community-based older adults in Shanghai, China. Effects of message framing on HPV Vaccination decision-making: A Survey experiment among Chinese male college students. Epidemiological characteristics of rotavirus gastroenteritis in China: A systematic review of studies published from 2014 to 2023. Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial. Satisfaction with immunization services and factors associated with satisfaction among guardians of 0-6-year-old children in China: A cross-sectional study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1